(Q51098678)

English

Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-M

scientific article published on 29 March 2014

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24682421%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial) (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24682421%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference

based on heuristic

inferred from title

myelodysplastic syndrome

1 reference

based on heuristic

inferred from title

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24682421%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24682421%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

author name string

R Willemze

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24682421%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

S Suciu

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24682421%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

P Muus

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24682421%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

C J M Halkes

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24682421%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

G Meloni

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24682421%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

L Meert

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24682421%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

M Karrasch

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24682421%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

J Rapion

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24682421%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

T de Witte

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24682421%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

J P Marie

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24682421%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

publication date

29 March 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24682421%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Annals of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24682421%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

93

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24682421%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24682421%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

965-975

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24682421%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2056-6

21 January 2018

High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2056-6

21 January 2018

Cytarabine dose for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2056-6

21 January 2018

Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2056-6

21 January 2018

Therapeutic advances in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2056-6

21 January 2018

Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2056-6

21 January 2018

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2056-6

21 January 2018

Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2056-6

21 January 2018

The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2056-6

21 January 2018

European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2056-6

21 January 2018

Biochemical modulation of cytarabine triphosphate by clofarabine.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2056-6

21 January 2018

Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2056-6

21 January 2018

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2056-6

21 January 2018

Clofarabine combinations as acute myeloid leukemia salvage therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2056-6

21 January 2018

Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2056-6

21 January 2018

Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2056-6

21 January 2018

Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2056-6

21 January 2018

Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2056-6

21 January 2018

Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2056-6

21 January 2018

Design and analysis of phase I clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2056-6

21 January 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-014-2056-6

21 January 2018

Identifiers

10.1007/S00277-014-2056-6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24682421%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24682421%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51098678&oldid=1519715613"